egfr/her1

Anti-ERBB1/EGFR/HER1 Antibody is a human-derived antibody expressed in CHO cells, targeting ERBB1/EGFR/HER1. It possesses a human IgG1 heavy chain and a human κ light chain, with an estimated molecular weight (MW) of 145 kDa. For an isotype control, refer to HumanIgG1kappa, Isotype Control.

Anti-ERBB1/EGFR/HER1 Antibody (7A7) is a humanized antibody produced in CHO cells, specifically targeting ERBB1/EGFR/HER1. It features a muIgG1 heavy chain and an mκ light chain, with a predicted molecular weight (MW) of 150 kDa. For isotype control, refer to HumanIgG1kappa, Isotype Control.

Trastuzumab is a humanized monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has been clinically used to treat HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer.

Cetuximab (C225) is a monoclonal antibody that is an inhibitor of human epidermal growth factor receptor (EGFR) (Kd=0.201 nM). Cetuximab has antitumor activity, inhibiting tumor cell proliferation and inducing apoptosis.

Panitumumab is a fully human IgG2 monoclonal antibody targeting the epidermal growth factor receptor EGFR).

Laprituximab emtansine (IMGN-289), an immunotoxin targeting HER1, is an EGFR antibody-drug conjugate (ADC) composed of J2898A antibody, DM1 (anti-microtubule agent), and the SMCC thioether linker, utilized in cancer research [1] [2] [3].

Matuzumab (EMD 72000) is a humanized monoclonal antibody targeting EGFR with potential anticancer activity that blocks EGFR activation and downstream signaling for the study of non-small cell lung cancer.